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Abstract
Toxicogenomics promises to aid in predicting adverse effects, understanding the mechanisms of drug action or toxicity, and
uncovering unexpected or secondary pharmacology. However, modeling adverse effects using high dimensional and high
noise genomic data is prone to over-fitting. Models constructed from such data sets often consist of a large number of
genes with no obvious functional relevance to the biological effect the model intends to predict that can make it
challenging to interpret the modeling results. To address these issues, we developed a novel algorithm, Predictive Power
Estimation Algorithm (PPEA), which estimates the predictive power of each individual transcript through an iterative two-
way bootstrapping procedure. By repeatedly enforcing that the sample number is larger than the transcript number, in each
iteration of modeling and testing, PPEA reduces the potential risk of overfitting. We show with three different cases studies
that: (1) PPEA can quickly derive a reliable rank order of predictive power of individual transcripts in a relatively small
number of iterations, (2) the top ranked transcripts tend to be functionally related to the phenotype they are intended to
predict, (3) using only the most predictive top ranked transcripts greatly facilitates development of multiplex assay such as
qRT-PCR as a biomarker, and (4) more importantly, we were able to demonstrate that a small number of genes identified
from the top-ranked transcripts are highly predictive of phenotype as their expression changes distinguished adverse from
nonadverse effects of compounds in completely independent tests. Thus, we believe that the PPEA model effectively
addresses the over-fitting problem and can be used to facilitate genomic biomarker discovery for predictive toxicology and
drug responses.
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Introduction
Many preclinical candidate compounds do not achieve
regulatory approval because of organ toxicity and lack of adequate
safety margins. Up to half of these compounds are terminated
from development due to hepatotoxic effects including necrosis,
steatosis, cholestasis, proliferation, inflammation, and bile duct
hyperplasia (BDH) [1]. It has been well-documented that
biomarkers that identify incipient damage that lead to preclinical
and clinical toxicities will enable better decision-making during
drug development [2]. Particularly valuable are translational
biomarkers that bridge preclinical testing species and humans as
they can expand the usefulness of the former for detection of
human liabilities [3].
Although a sole biomarker is appealing as it can be less
expensive to measure, and the results are easier to interpret than a
panel of markers, there are few examples in preclinical testing or in
clinical practice wherein a single measurement is considered
definitive for target organ toxicity. Multiple markers are required
to capture the biological heterogeneity of organs involved,
individual variations and disease or toxicity processes [4].
Microarray technology allows us to observe and assess the
expression of thousands of genes simultaneously in each sample
and machine learning algorithms can be applied to identify gene
signatures or biomarkers from microarray data. Numerous recent
studies have demonstrated that gene expression signatures not only
outperform traditionally used clinical parameters in toxicity or
disease outcome prediction, but also contribute to a better
understanding of the biological mechanism [5–10]. However,
gene signatures proposed to be correlated to the same biological
phenotype by different researchers differ widely and often have
very few genes in common [11–12]. This lack of congruence raises
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24233doubts about the reliability and robustness of the reported
predictive signatures. Analysis of the situation has led to
suggestions that the different gene sets may result, at least in part,
from over-fitting [13–15]. Over-fitting is a concern when the
number of training samples is small and the number of genes
relatively large, as in this situation it is straightforward to obtain a
classifier that correctly describes the training data, but performs
poorly on an independent set of data.
Over-fitting has been closely examined in several studies [16–
17]. Two studies in logistic and Cox regression showed increasing
bias and variability, unreliable confidence interval coverage, and
problems with model convergence as events per variable (EPV)
declined below 10, and especially below five, leading to the rule of
thumb that logistic and Cox models should be used with a
minimum of 10 EPV [18–19]. Therefore, feature selection is
commonly performed before sample classification is even attempt-
ed to alleviate the above stated problem. Although numerous
reports for feature selection have been published, and some
techniques have been claimed better than others [13,20–22], to
date, no single recommendation in the literature is given for
methods in either the feature selection or the classification of
microarray data [22-23].
Feature selection algorithms fall mainly into two broad
categories, the filter model or the wrapper model [24–26]. The
widely accepted filter techniques are single-feature based and have
been demonstrated to be effective for improving sample
classification accuracy. Some of them are statistical tests (t-test,
F-test) [27], non-parametric tests like TNoM [28], S2N ratio
(signal to noise ratio) [29], etc. However, these methods share a
limitation in that the interaction with classifier and feature
dependencies has been completely ignored. However, interactions
between genes are important for numerous - if not all - biological
functions [30–31]. Although the wrapper methods use the
interactions between features, perform multivariate gene subset
selection, and incorporate the classifier’s preference or bias into
the search and thus offer an opportunity to construct more
accurate classifiers, the disadvantages are that they are computa-
tionally intensive, result in classifier dependent selection, and are
at a particularly high risk of over-fitting [22]. In the present study,
we describe the development of a new method, Predictive Power
Estimation Algorithm (PPEA), to evaluate and rank the relative
predictive power of individual genes. By applying PPEA to the
DrugMatrix
TM chemogenomic database, we identified and
validated three small sets of genes highly predictive of, and
functionally related to, liver inflammation (INFL), necrosis and
bile duct hyperplasia (BDH), respectively. Furthermore, we
successfully converted a 3-gene signature to a multiplex qRT-
PCR assaythat can be effectively deployed as a genomic biomarker
to predict BDH.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and local animal
welfare bodies, and all animal work was approved by the Lilly’s
Institutional Animal Care and Use Committee under IACUC
protocol 2008-0727.
Algorithm
Figure 1 shows the PPEA algorithm. Let MP|N be the
expression data matrix of P genes as rows and N samples as
columns, among which N1 samples are labeled as T1,T2,:::TN1for
toxicity class and N2 samples labeled as NT1,NT2,:::NTN2 for
non-toxicity class. Thus, N~N1zN2. Let a be a predetermined
threshold of acceptable classification error rate of model testing
and b be the arbitrarily defined sample split ratio to construct
training and testing sample sets. Let K be the total number of
iterations and k be the kth iteration (k~1,2,:::,K). Let Ek
P|4be the
performance matrix estimated after the kth iteration consisting of P
rows, each of which is identified by the genes gi(i~1,2,:::,P)in the
data matrix MP|N, and four columns corresponding respectively
to Tk
i as the total number of times gi is sampled after kth iterations,
Sk
i as the total number of times gi selected in the successful
predictive modeling (see Step 3a below for definition) after kth
iterations, Pk
i ~Sk
i =Tk
i as an estimate of the predictive power of gi
after the kth iterations, and Rk
i where i5(1,2,:::,P) as estimated
rank order of gi based on its estimated predictive power Pk
i after
the kthiteration. Genes with larger Pk
i are more predictive than
those with smaller Pk
i and thus ranked higher. At the initiation of
the algorithm, E0
P|4~½0 . For each iteration k~1,2,:::,K,
executes the following steps.
Step 1: Apply two-way bootstrapping to the MP|N to obtain a
bootstrapping sample matrix Sk
p|n consisting of p genes,
gj(j~1,2,:::,p), randomly drawn from P genes, n1 samples from
N1 samples of toxicity class and n2 samples from N2 samples of
non-toxicity class such that n1=N1~b,n2=N2~b, n~n1zn2 and
pvn. n is the sample size of training sample set while (N{n) is the
sample size of testing sample set.
Step 2: Apply Prediction Analysis of Microarray (PAM) to the
bootstrapping sample matrix Sk
p|nto perform sample classification
using the nearest shrunken centroid method [32]. To build a
predictive PAM model, ten-fold cross validation was performed to
determine the optimal classifier performance which minimizes
classification errors for the training set Sk
p|n Based on the ten-fold
cross validation, a threshold Dk was varied in search of the optimal
classifier performance. The Dk is chosen when the lowest
classification errors achieved with the fewest genes g1,g2,:::,gl
where lƒp. The resultant PAM model in the current kth iteration
mk~f(g1,g2,:::,g1) lƒp ð1Þ
is subsequently tested using the (N{n) testing samples. Let e be
the error rate of the kth modeling when tested with the testing
samples and estimated by (2).
ek~
false positiveszfalse negatives
N{n
ð2Þ
In cases where cross validation errors are greater than a for all
possible Dk value, i.e., no acceptable PAM model can be
constructed from genes g1,g2,:::,gl where lƒp for the training
samples, the independent model test using (N{n) testing samples
described above is omitted and the execution proceeds to Step 3b
described below.
Step 3a: If ekƒa, i.e., the estimated error rate of the model
tested with (N{n) testing samples is less than the predetermined
threshold, the model is deemed to be predictive and thus a
successful modeling. The performance matrix EP|4 is updated as
follows. Each gene, gj(j~1,2,:::,p), in the bootstrapping samples
Sk
p|nis mapped to gi(i~1,2,:::,P) in EP|4, Tk
i , Sk
i , and Pk
i are
updated sequentially as follows:
Tk
i ~
Tk{1
i z1 if gi[(g1,g2,:::,gp)
Tk{1
i if gi  [ [(g1,g2,:::,gp)
(
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i ~
Sk{1
i z1 if gi[(g1,g2,:::,gl)
Sk{1
i if gi  [ [(g1,g2,:::,gl)
(
Pk
i ~Sk
i =Tk
i
Step 3b: On the contrary, if ekwa, i.e., the estimated error rate
of the model tested with (N{n) samples is larger than the
predefined threshold, the model is deemed to be not predictive for
independent testing samples. The model constructed is over-fitting
and thus is discarded. Tk
i , Sk
i , and Pk
i in the performance matrix
EP|4 are updated sequentially as follows:
Tk
i ~
Tk{1
i z1 if gi[(g1,g2,:::,gp)
Tk{1
i if gi  [ [(g1,g2,:::,gp)
(
Sk
i ~Sk{1
i
Pk
i ~Sk
i =Tk
i
Sort Pk
i decreasingly, i.e., Pk
gi1
§Pk
gi2
§:::§Pk
gip, a rank order of
genes in term of their predictive power is given as
Rk~1,2,:::,P
Stop criterion. The rank order Rk is evaluated periodically,
say every 10000 iterations, by computing Spearman correlation
coefficient between the current rank Rk and the previous rank Rk’,
which is the previous rank order after the k’
th iterations, i.e.,
r~1{6
XP
i~1
(Rk
i {Rk’
i )
2
P(P2{1)
The algorithm stops if rw0:99, i.e., the iteration stops when the
rank is stabilized.
Case studies
DrugMatrix
TM is a chemogenomics database originally devel-
oped by Iconix Pharmaceuticals, now owned by Entelos, Inc. [33].
In a typical DrugMatrix
TM toxicology study, three rats in each
combination of dose and time point (defined as a treatment) were
Figure 1. Schematic representation of PPEA algorithm. Assumptions used in the schema are (1) the original data matrix consists of (20 toxic
and 20 non-toxic samples) x1000 genes, and (2) a 2-way bootstrapping sample consists of 10 toxic and non-toxic samples (i.e. K splitting ratio) and
10 genes.
doi:10.1371/journal.pone.0024233.g001
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profiles using the RU1 microarray (Agilent). All data were
MIAME compliant and raw data have been previously deposited
to a MIAME compliant database, GEO, accession GSE8858 [34].
An average profile representing each treatment, defined as a
sample, was computed from the three biological replicates. The
PPEA algorithm was tested using data from DrugMatrix
TM studies
that resulted in three different liver toxicities, namely bile duct
hyperplasia (BDH), necrosis, and inflammation (INFL). For each
toxicity phenotype, two classes of compounds were identified by
querying the DrugMatrix
TM database based on severity and
incidence of the phenotype they induced. A compound was
classified into the positive class if its p-value of observed idit score
[35–36] for a given phenotype is less than or equal to 0.01 and the
percentage of incidence is 100. The ridit analysis is a statistical
technique that works with ordered categorical data by evaluating
categories in terms of their frequency of occurrence in a control or
reference group [35–36]. Conversely, a compound was classified
into the negative class if its p-value of observed ridit score for a
given phenotype is larger than 0.5 and percentage of incidence is
0. Compounds with intermediate p-values and percentage of
incidences were excluded from the analysis. These high stringency
criteria provided us with a reliable identification of robust positive
and negative classes of samples for modeling. Note that a single
compound may contribute multiple samples for analysis owing to
different time and dose combinations which pass the query
criteria. The number of compounds and treatments in the positive
class for each phenotype are listed in Supporting Information
Table S1.
The Uniset Rat I Expression (RU1) microarrays used for the
experiments described here were purchased from Amersham
Biosciences (Piscataway, NJ, now part of GE Healthcare, USA).
The RU1 BioArray contains 9911 nucleotides probes (30-mer)
with 8565 probes used for data analysis. Previous studies [34,37]
have shown that low-abundant transcripts tend to be much more
variable than abundant ones. Thus, three filters were applied to
obtain informative transcripts for the modeling process. An
informative transcript is defined as one with: (1) average expression
larger than 2 on a 1 to 5 scale defined in DrugMatrix
TM, (2)
absolute fold changes larger than or equal to 1.5, and (3) a p-value
less than 0.05 when the treatment group is compared with the
vehicle using Student t-test. Using these criteria, 4231 informative
transcripts were identified.
Pathway analysis
The most predictive, i.e., top-ranked 20 genes, from each case
study were analyzed using Ingenuity Pathway Analysis tool
(purchased from Ingenuity Systems, Redwood, CA) to assess their
potential functional relevance with the liver toxicity phenotype
which the gene set was intended to predict.
Generation of predictive model from the top-ranked
genes by PPEA
PPEA was implemented in the R release 2.9 (http://www.r-
project.org/, the R code is provided as Supporting Information
Text S1). For each case study, the top-ranked 10 genes with all
samples were used as an initial input to train PAM models. The
smallest model was obtained with an arbitrarily pre-determined
acceptable error rate, i.e. #20%, based on the ten-fold cross-
validation. In cases that such a model did not exist due to
unacceptably high error rates, i.e. .20%, expanded top-ranked
genes such as 15, 20 or more may be attempted. For all cases in
the present study, we found the top 20 genes were sufficient to
obtain a predictive model for each toxicity phenotype with
acceptable error rates based on the 10-fold cross validation. The
resultant model obtained in this way is called the PPEA-PAM
model to distinguish it from the PAM model without feature
selection by PPEA.
For each case study, we compared our model with the best
PAM model without applying PPEA as well as with the respective
gene signatures of DrugMatrix
TM, which were developed by
sparse-SVM [33–34]. Sensitivity, specificity, positive and negative
predictive values (PPV and NPV respectively) of the PPEA-PAM
model were compared with those of PAM and DrugMatrix
TM
gene signatures.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
Total RNA was isolated from banked frozen rat livers from the
same studies used to generate DrugMatrix
TM RNA profiles by
placing ,0.3 mg of liver in 800 ml of RLT lysis buffer (RNeasy
minikit Qiagen) in Lysing D matrix tubes and homogenized using
a Fastprep FP-120 tissue homogenizer (Bio101 Systems). Based on
their expression difference between positive and negative classes in
the microarray study, three genes (RhoC, Jub, and Pspla1) were
selected from our PPEA-PAM model for BDH for validation by
quantitative real-time RT-PCR (qPCR). A housekeeping gene
peptidylpropyl isomerase b (Ppib), also known as cyclophilin, is
used as a control gene because this gene is reported as an
endogenous reference for gene expression analysis [38-39].
Primers were designed with Primer Express software and
purchased from Applied Biosystems (Palo Alto, CA, USA). For
qPCR, 1 mg total RNA was reverse transcribed in a final volume
of 50 ml using high capacity cDNA reverse transcription reagents
(Applied Biosystems) with random hexamer primers according to
manufacturer instructions. Reactions excluding MultiScribe Re-
verse Transcriptase (Applied Biosystems) were performed as
negative controls. cDNA targets at a 50-fold final dilution were
amplified in three replicate wells in an ABI 7900 Sequence
Detector System (Applied Biosystems) with the following thermal
profile: 50uC for 2 min, 95uC for 10 min, followed by 40 cycles of
15 sec at 95uC and 1 min at 60uC. Standard curves for each gene
were obtained by amplifying (in triplicates) 5-fold serial dilutions of
a reference mixture containing cDNA derived from treated and
control tissues.
Confirmation of predictive value of the top-ranked genes
by PPEA
To independently validate the predictive value of the top-
ranked genes by PPEA, for each case study, we selected
compounds originating from our internal drug development
programs which were terminated due to observed rat liver toxicity
(i.e. BDH, INFL or Necrosis). Compounds which did not display
the indicated toxicity phenotype were also identified and served as
negative controls. Total RNA was prepared from rat livers of
selected animals and approximately 5 mg of total RNA was
reversed transcribed into cDNA using a Superscript II Double-
Strand cDNA Synthesis Kit (Invitrogen Life Technologies). 5mgo f
which was used to hybridize Affymetrix rat genome DNA hip
RAE2302 430A 2.0, which contains sequences corresponding to
roughly 22,600 transcripts, according to Affymetrix protocol
(http://www.affymetrix.com/support/technical/manuals.affx). An
Affymetrix fluidics station 400 was used for array washing and
staining, and an Agilent GeneArray scanner 3000 was for scanning.
Each sample was hybridized to a single microarray. Expression of
selected genes for each case study was obtained from the DNA chips
and analyzed using principal component analysis (PCA), and also
A New Algorithm for Genomic Biomarker Discovery
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Support Vector Machine (SVM). The sensitivity, specificity, and
accuracy were calculated.
Results
Estimation of predictive power of individual transcripts
by PPEA
Two-way re-sampling with replacement or bootstrapping was
applied to the data matrix iteratively as described above in the
algorithm section. As shown in Figure 2(A), all transcripts had an
equal chance to be evaluated for its predictive power by the PPEA
algorithm, as expected by design. The total number of evaluations
for each transcript is proportional to the total number of iterations
executed. For example, on average each transcript was evaluated
300 times for a total of 20,000 iterations, which increased to 1500
and 3000 times respectively for a total of 100,000 and 200,000
iterations. Different transcripts have different predictive power, as
shown in Figure 2(B), when measured by the total number of
successful modeling iterations, i.e. their error rates computed from
the testing samples are less than an arbitrarily determined
threshold a~20%. The differences in successful product was
small (compare the left and the right ends of the blue plot of
Figure 2(B)) when the total number of iterations was low, for
example 20,000. Then the differences increased and became
obvious as the total number of iterations increased, as shown by
magenta and pink plots in Figure 2(B). Such dependency on the
total number of iterations disappeared when normalized to the
total number of times each transcript was evaluated (Figure 2(C)).
Thus, PPEA can quantify the predictive power of a large number
of transcripts.
In principle, PPEA has to evaluate all C
p
P~ P{1 ðÞ !=
p{1 ðÞ ! P{p ðÞ ! possible combinations of p out of P transcripts,
which is an OP ! ðÞ algorithm, in order to estimate the true
predictive power of a transcript. Thus, it is of great interest to
determine if a relative rank order of predictive power of
transcripts can be reliably obtained by the bootstrapping
procedure. Using BDH as an example, we first executed
320,000 iterations of PPEA to obtain a distribution of predictive
power of all transcripts and then obtained a rank order based on
their estimated predictive power sorted in decreasing order. We
compared the rank orders similarly obtained from a smaller
number of iterations. As shown in Figure 3A, the rank order of
predictive power for BDH among the top ten transcripts were
Figure 2. Analysis of sampling distribution in the predictive power enrichment matrix. (A) A random number generator with a uniform
distribution was used so that each of 4000 features (genes) had equal chances to be sampled. Y axis is the total # of times a gene was sampled,
represented as T. (B) A prediction was called a success if overall error rates , a, which is 20%. Y axis is the total # of times a gene was included in a
successful modeling, denoted as S. (C) Y axis is the Relative Success Rate that a gene was used in successful modeling, computed as R=S/T, which is a
metric to measure the predictive power of the gene.
doi:10.1371/journal.pone.0024233.g002
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order of the top 10 genes was largely stabilized after 180K
iterations without significant changes (Figure 3B). Similar results
were obtained for INFL and necrosis. Thus, PPEA can reliably
obtain a relative rank order of the most predictive transcripts
using a relatively small number of iterations.
Assessment of the top ranked transcripts
Most of the reported gene signatures derived purely mathe-
matically consist of many genes with either no functional
annotation (e.g. EST’s) or no obvious functional relevance to
the phenotype they predict [11–12]. We believe this may, at least
partially, originate from overfitting. To assess if PPEA selects
genes that were associated or correlated to the toxicity phenotype,
we performed pathway analysis of the twenty top ranked genes
for BDH, Necrosis, and INFL (see Supporting Information Table
S2 for detail) using Ingenuity Pathway Analysis tools (IngenuityH
Systems, www.ingenuity.com). As shown in Figure 4A for BDH,
eleven out of the twenty top ranked genes participate in the cell
proliferation interaction network. They have either direct or
indirect functional interactions with powerful mitogenic factors
such as ERBB2, a well-known member of the epidermal growth
factor (EGF) receptor family of receptor tyrosine kinases.
Amplification and/or over-expression of this gene has been
reported in numerous cancers, including breast and ovarian
tumors [40–41]. Similarly, as shown in Figure 4B for INFL,
seventeen out of the twenty top ranked genes were mapped to the
inflammation and immune response network where they directly
or indirectly interact with the key inflammatory regulator NFkB
[42]. Interestingly, the highest scoring network represented within
the top twenty ranked genes for necrosis related to immune
response, linking 9 necrosis-associated genes to the well defined
inflammatory NFkB pathway (Figure 4C). A second network links
3 members of these top 20 necrosis genes to cell death and cell
cycle (Figure 4D). This result implies that liver necrosis is strongly
associated with, or resulted in, the hepatic inflammation, which is
a common finding with liver damage, including drug-induced
liver toxicity [43]. Importantly, about one third (14) of the
positive compounds in this study caused both inflammation and
necrosis at a different time period and/or dose level than those
that reported just necrosis. Thus, it is clear that the most
predictive genes identified by PPEA tend to be functionally
related to the phenotype they predict, which is generally not true
for gene signatures derived by other methods.
Figure 3. Example of top 10 genes Rank shifting at each checkpoint of the iteration. (A) shows that the index of the 10 top-ranked genes
(i.e., features) becomes stabilized when the iteration of splitting reached 280k. The rank for 8 out of 10 genes is consistent as early as the iteration
reaches to 180k. (B) A plot for the same data as shown in (A) for an intuitive observation.
doi:10.1371/journal.pone.0024233.g003
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Iconix Inc. using sparse-linear regression or SVM are highly
predictive of phenotype [33,44]. However, they typically consist of
dozens or even hundreds of transcripts. Because of the bulky size
of the gene signatures, it would be difficult for users to develop
alternative assay formats, for example multiplex qRT-PCR, to
facilitate fast compound screening in the early stages of drug
development. Considering the plate size, number of replicates and
throughput, an assay multiplexed with five to ten genes is desirable
in practice. Rank order of predictive power of individual
transcripts obtained by applying PPEA aids in selecting a small
number of transcripts. The question is whether the top ranked
small number of genes can still effectively predict toxicity
phenotype. To answer this question, we first developed the
minimum signature, called PPEA-PAM, for the liver toxicity
phenotypes of BDH, necrosis, and INFL, and progressively
selected from 10, 15 or 20 top-ranked transcripts. Next, we
compared performance of PPEA-PAM with that of PAM and
corresponding DrugMatrix
TM gene signatures derived from the
full set of transcripts. As shown in Table 1, PPEA-PAM was
comparable to, or significantly outperformed PAM and DrugMa-
trix
TM gene signatures, in terms of overall error rates, sensitivities
and specificities.
Early prediction of BDH is challenging in short duration
toxicology studies when reliant solely on histology and clinical
chemistry as true hyperplasia may require a longer timeframe to
manifest, thus better predictive methods are needed. We validated
the expression of the three genes in the PPEA-PAM gene signature
for BDH using qRT-PCR. As shown in Figure 5, positive BDH
samples could be clearly distinguished from the negative samples
across all samples used in signature derivation simply using the
three gene signature.
Figure 4. Ingenuity Pathway Analysis (IPA) for the enriched biological functions of the top 20 genes for each signature. The involved
genes are highlighted in the red color. The lines between genes represent known interactions, with solid lines representing direct interactions and
dashed lines representing indirect interactions. The high scores associated with these networks indicate they were highly unlikely to be formed by
chance. (A) 11 out of the top 20 genes for BDH signature are involved with p53 and ERBB2 pathways (Network 1, Cancer, Cell Cycle, Cell Death, score
of 28), and (B) 17 out of the top 20 inflammation signature genes are involved with inflammatory pathway NFkB (Network 1, Immune Response, Cell-
To-Cell Signaling and Interaction, Connective Tissue Disorders, score of 47). (C) 9 of the top 20 genes for the necrosis signature are also involved with
Immune Response pathway, majorly NFkB complex, and (D) 3 of the top 20 genes for necrosis are associated with cell death (Network 2, Cancer, Cell
Death, Cell Cycle, score of 6).
doi:10.1371/journal.pone.0024233.g004
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To independently confirm that the genes selected by PPEA-
PAM using DrugMatrix
TM data are predictive for BDH, Necrosis,
and INFL, we identified compounds originating from our drug
development programs that were terminated due to observed
adverse findings in liver (i.e. BDH, Necrosis, or INFL).
Compounds which did not display the indicated toxicity
phenotype were also identified and served as negative controls.
Liver expression profiles of rat treated with these compounds were
generated using Affymetrix DNA chips. Expression of the top 10
genes predictive for BDH, INFL, and necrosis were analyzed using
PCA. As shown in Figure 6A, 6B, and 6C, BDH-, Necrosis-, and
INFL- inducing compounds can be clearly separated from non-
inducing compounds by expression changes of a small number of
highly predictive genes. The detail information for each model
performance is listed in Figure 6D.
Discussion
A recurring question when working with microarray data is how
to manage the ubiquitous ‘‘overfitting’’ in gene expression
profiling. Because of the uniqueness of microarray data, wherein
the sample size is typically far smaller than the feature size, this
situation necessitates dimensionality reduction through gene
selection to avoid overfitting and improve the generalization of
discriminant analysis. In this paper, we propose a novel feature
selection algorithm termed PPEA to tackle this fundamental issue.
PPEA first applies two-way bootstrapping to manage the number
Table 1. A comparison of the performance of 3 different signatures for detecting Necrosis, Bile Duct Hyperplasia, and
Inflammation.
Rate (%) P-value *
Performance Signature Necrosis INFL BDH Necrosis INFL BDH
Sensitivity PPEA-PAM 85.10% 84.40% 95.30% NA NA NA
PAM 84.60% 82.00% 91.30% 1.59E-01 2.58E-14 1.94E-23
ICONIX 81.70% 80.50% 93.40% 2.17E-18 1.32E-32 3.55E-07
Specificity PPEA-PAM 75.90% 75.50% 94.50% NA NA NA
PAM 75.10% 72.20% 90.90% 9.12E-04 9.05E-44 1.11E-20
ICONIX 73.90% 69.60% 88.10% 1.39E-12 1.5E-120 2.09E-57
Error rate PPEA-PAM 20.50% 20.90% 5.50% NA NA NA
PAM 21.20% 23.90% 9.50% 1.03E-02 6.00E-34 3.98E-30
ICONIX 23.00% 26.30% 10.00% 5.44E-17 1.19E-92 1.56E-38
*P value is generated from student t – test when comparing the percentage of sensitivity, specificity, and error rate for PPEA-PAM with that for PAM or ICONIX signature.
doi:10.1371/journal.pone.0024233.t001
Figure 5. qPCR. (A) Boxplots represent normalized mRNA expression of the top three genes for BDH signature determined by RT-qPCR. The box
represents the 25th and 75th percentile range of scores. A vertical line in each box represents the median value of the normalized mRNA of each
group. The whiskers represent the highest and lowest values. The box highlighted with red and blue colors indicates the group of animals treated
with BDH positive (n=18) or negative compounds (n=30), respectively. (B) Principal components analysis (PCA) shows that there is a clear separation
between the positive and negative classes based on the expression level of top 3 genes in BDH signature. GOI = Gene of Interest.
doi:10.1371/journal.pone.0024233.g005
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each splitting subset used for machine learning, and then assesses
the merit of each individual feature by evaluating its strength of
class predictability under this new low dimensional sample-feature
space. This approach is different from the other feature selection
algorithms in that it assesses predictive power of individual genes
within the context of a multivariate model. Accordingly, this
enables PPEA to access the gene information contained in
complex biological interactions, rather than relying on the
summation of univariate relationships within a set. For example,
if two genes in a category were related to the samples’ biological
process or state by an ‘exclusive OR’ association, then PPEA could
capture that relationship, whereas filter-based summations of
univariate associations would likely overlook it.
The task of conventional feature selection in microarray analysis
is considered as a search problem where each state in the search
specifies a distinct subset of the possible relevant features. If the
search space is too large, it is possible that the algorithm cannot
discover the most selective genes within the search space.
Moreover, having too many redundant or irrelevant genes
increases the risk of overfitting, computational complexity and
cost and, ultimately, degrades estimation in classification error.
The PPEA algorithm described here, in concept, approaches the
search space in a ‘‘divide and conquer’’ fashion, breaking down
the search space into a large number of sub-spaces of the same (or
related) type. These sub-spaces with a new dimensionality (the
sample size is now larger than the feature size) are thus able to
minimize over-fitting. The solutions to the sub-space are then
combined to give a solution to the original space. In practice, we
realize that the random data split in each iteration may create
circumstances where different runs of the algorithm may select
different features if the number of iterations is small. An
unfortunate split of the data set may also remove an important
feature, thus negatively affecting the classifier’s performance.
Fortunately, this situation can be avoided if the number of
iterations is large enough. We do not claim that our PPEA
methods will find all interesting genes, because the schema for
feature search in this algorithm is heuristic and suboptimal as it
Figure 6. Validation with an independent dataset. Visual representation of PCA results for the top 10 genes in the BDH (A), INFL (B), and
necrosis (C) signatures validated with independent samples. The result shows a clear separation between positive and negative compounds; (D)a
SVM classifier performance matrix shows that a reasonable sensitivity (from 80% to 88%) and specificity (from 78% to 81%) have been achieved for
each model. TP - True Positive;F N-False Negative;F P-False Positive;T N-True Negative; SENS - Sensitivity; SPEC - Specificity; ERR - Error rate; NECR -
Necrosis.
doi:10.1371/journal.pone.0024233.g006
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combinations. However, we demonstrated that the rank transition
became a plateau and that the majority of features ranked at the
top positions were very stable after a certain number of iterations
were searched. In our algorithm, the iteration is terminated when
the stability of ordered features according to their predictive power
within each predictive power enrichment matrix is reached
(Figure 3).
A key and pivotal finding from the PPEA analysis is that it
provides insight into the biological mechanisms for a phenotype of
interest. The functional analysis demonstrates that the signature
genes tend to be mechanistically related to the phenotype the
signature is intended to predict, i.e. associated with mechanism of
toxicity. For example, BDH manifests a purely cholangiolar
proliferation considered as a pre-neoplastic lesion usually as a
result of exposure to carcinogenic compounds such as Phomopsin
[45]. Our results show that 11 of the top 20 genes for the BDH
signature are associated with key regulators of cell proliferation, for
example, ERBB2 (Figure 4A). We also observed that 17 out of the
top 20 genes for the ‘‘INFL’’ and 9 of the top 20 genes for the
‘‘Necrosis’’ signatures identified by PPEA were members of the
NFkB interactive network (Figure 4B and 4C). This finding further
confirms that immune responses and associated autoimmunity can
play an important role in both predictive (acute) and idiosyncratic
drug-induced liver injuries [43]. We believe that our approach
provides a novel method to find genes that truly reflect the
biological consequences of a therapeutic intervention or disease.
Furthermore, the fact that the PPEA method provides gene sets of
limited number allows for the use of non-microarray methods such
as qPCR which greatly reduces cost and improves on turn-around
times for data generation and analysis. Herein, we have
demonstrated with our liver injury datasets that quite accurate
diagnoses for several distinct phenotypes could be achieved using
the gene-expression level results of only 5 - 20 genes.
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